Trial Profile

Phase II, Randomised, Double-Blind, Two-Arm, Parallel Study of Vandetanib (ZACTIMA, ZD6474) Plus Gemcitabine (Gemzar) or Gemcitabine Plus Placebo as First Line Treatment of Advanced (Stage IIIB or IV) Non Small Cell Lung Cancer (NSCLC) Elderly Patients.

Status: Completed

Phase of Trial: Phase II

Latest Information Update: 21 Oct 2016

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

01 May 2014 Results published in the Journal of Thoracic Oncology.
02 Jun 2012 Results presented at the 48th Annual Meeting of the American Society of Clinical Oncology.
27 Mar 2012 Actual end date (Dec 2011) added as reported by ClinicalTrials.gov.

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com